VivoSeq
Neurology

Progressive Multiple Sclerosis

3

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Progressive Multiple Sclerosis is an early-stage landscape with 3 programs across 3 companies. The most active players are Roche, Eli Lilly, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Novartis logo

Novartis

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Rapcabtagene Autoleucel

Novartis

Phase 1
No programs
Phase 22

RO7268489

Roche

Ocrelizumab

Roche

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

3programs
Small molecule133%
Monoclonal antibody133%
Cell therapy133%

Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

An Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression, and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Recruiting·Novartis logoNovartis·Preclinical·NCT06675864·28 enrolled
A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis
Recruiting·Roche logoRoche·Phase 2·NCT07282574·360 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)